Johnson & Johnson (JNJ)vsQiagen NV (QGEN)
JNJ
Johnson & Johnson
$232.77
-2.08%
HEALTHCARE · Cap: $536.54B
QGEN
Qiagen NV
$36.68
-2.34%
HEALTHCARE · Cap: $7.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 4491% more annual revenue ($96.36B vs $2.10B). JNJ leads profitability with a 21.8% profit margin vs 19.2%. QGEN appears more attractively valued with a PEG of 0.93. QGEN earns a higher WallStSmart Score of 61/100 (C+).
JNJ
Buy59
out of 100
Grade: C
QGEN
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Margin of Safety
-26.4%
Fair Value
$40.38
Current Price
$36.68
$3.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 23.8%
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
1.8% revenue growth
Earnings declined 23.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : QGEN
The strongest argument for QGEN centers on PEG Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 19.2% and operating margin at 23.8%. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : QGEN
The primary concerns for QGEN are Revenue Growth, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while QGEN is a value play — different risk/reward profiles.
QGEN carries more volatility with a beta of 0.66 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
QGEN scores higher overall (61/100 vs 59/100), backed by strong 19.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Qiagen NV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?